CN110049983B - 药物化合物 - Google Patents
药物化合物 Download PDFInfo
- Publication number
- CN110049983B CN110049983B CN201780072401.XA CN201780072401A CN110049983B CN 110049983 B CN110049983 B CN 110049983B CN 201780072401 A CN201780072401 A CN 201780072401A CN 110049983 B CN110049983 B CN 110049983B
- Authority
- CN
- China
- Prior art keywords
- dimethylisoxazol
- pyrrolidin
- imidazol
- benzo
- difluorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1617630.7A GB201617630D0 (en) | 2016-10-18 | 2016-10-18 | Pharmaceutical compounds |
| GB1617630.7 | 2016-10-18 | ||
| PCT/GB2017/053152 WO2018073586A1 (en) | 2016-10-18 | 2017-10-18 | Pharmaceutical compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110049983A CN110049983A (zh) | 2019-07-23 |
| CN110049983B true CN110049983B (zh) | 2022-06-14 |
Family
ID=57680668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780072401.XA Active CN110049983B (zh) | 2016-10-18 | 2017-10-18 | 药物化合物 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10696666B2 (https=) |
| EP (1) | EP3529248B1 (https=) |
| JP (1) | JP7152393B2 (https=) |
| KR (1) | KR102578786B1 (https=) |
| CN (1) | CN110049983B (https=) |
| AU (1) | AU2017346453B2 (https=) |
| CY (1) | CY1123666T1 (https=) |
| DK (1) | DK3529248T3 (https=) |
| EA (1) | EA201990643A1 (https=) |
| ES (1) | ES2828504T3 (https=) |
| GB (1) | GB201617630D0 (https=) |
| HR (1) | HRP20201444T1 (https=) |
| HU (1) | HUE052443T2 (https=) |
| IL (1) | IL266017B (https=) |
| LT (1) | LT3529248T (https=) |
| MX (1) | MX384438B (https=) |
| PT (1) | PT3529248T (https=) |
| RS (1) | RS61007B1 (https=) |
| SG (1) | SG11201903155XA (https=) |
| SI (1) | SI3529248T1 (https=) |
| SM (1) | SMT202000593T1 (https=) |
| WO (1) | WO2018073586A1 (https=) |
| ZA (1) | ZA201902334B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201617627D0 (en) * | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201617630D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| US11292791B2 (en) | 2017-09-15 | 2022-04-05 | Forma Therapeutics, Inc. | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors |
| GB201806320D0 (en) * | 2018-04-18 | 2018-05-30 | Cellcentric Ltd | Process |
| IL279734B2 (en) | 2018-06-29 | 2024-11-01 | Forma Therapeutics Inc | Inhibiting creb binding protein (cbp) |
| EP3937936A4 (en) * | 2019-03-15 | 2022-12-28 | Forma Therapeutics, Inc. | INHIBITION OF CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) |
| US12351577B2 (en) | 2019-03-15 | 2025-07-08 | Forma Therapeutics, Inc. | Inhibiting cyclic AMP-responsive element-binding protein (CREB) |
| CN112574178B (zh) * | 2019-09-27 | 2025-12-16 | 海创药业股份有限公司 | 一种氘代苯并咪唑类化合物及其作为ep300/cbp抑制剂的用途 |
| CN112574189B (zh) * | 2019-09-27 | 2024-05-31 | 海创药业股份有限公司 | 一种ep300/cbp抑制剂 |
| CN112574191B (zh) * | 2019-09-29 | 2024-01-23 | 南京圣和药业股份有限公司 | 异噁唑杂环类化合物及其应用 |
| AU2021298153A1 (en) | 2020-06-25 | 2023-02-23 | Tolremo Therapeutics Ag | A combination of a CBP/p300 bromodomain inhibitor and an EGFR inhibitor for use in treating EGFR-mutant NSCLC |
| IL299344A (en) | 2020-06-25 | 2023-02-01 | Tolremo Therapeutics Ag | Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer |
| US11795168B2 (en) | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
| US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
| TW202227429A (zh) * | 2020-11-06 | 2022-07-16 | 大陸商貝達藥業股份有限公司 | Ｐ３００抑制劑、包含其的藥物組合物、其應用及製備其的方法 |
| US20240122941A1 (en) * | 2020-12-25 | 2024-04-18 | National Cancer Center | Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer |
| US20240109879A1 (en) * | 2020-12-31 | 2024-04-04 | Medshine Discovery Inc. | Benzimidazole compound and application thereof |
| WO2022184664A1 (en) | 2021-03-02 | 2022-09-09 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
| CN114989158A (zh) * | 2021-03-02 | 2022-09-02 | 复旦大学 | 组蛋白乙酰转移酶p300溴结构域抑制剂及其药用组合物及其应用 |
| EP4257130A1 (de) * | 2022-04-08 | 2023-10-11 | Justus-Liebig-Universität Gießen | Inobrodib zur behandlung von pulmonaler arterieller hypertonie |
| CN117645603A (zh) * | 2022-09-05 | 2024-03-05 | 复旦大学 | p300溴结构域抑制剂及其药用组合物及其应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007056593A2 (en) * | 2005-11-08 | 2007-05-18 | Choongwae Pharma Corporation | α-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS |
| WO2011085039A2 (en) * | 2010-01-05 | 2011-07-14 | The Johns Hopkins University | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies |
| CN105324379A (zh) * | 2013-05-09 | 2016-02-10 | 吉里德科学公司 | 作为溴结构域抑制剂的苯并咪唑衍生物 |
| CN105492439A (zh) * | 2013-06-21 | 2016-04-13 | 齐尼思表观遗传学公司 | 作为溴结构域抑制剂的新取代的双环化合物 |
| WO2016086200A1 (en) * | 2014-11-27 | 2016-06-02 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ270985A (en) | 1994-04-29 | 1997-06-24 | Lilly Co Eli | Substituted benzimidazole derivatives; medicaments and preparation of medicaments |
| AU5636900A (en) * | 1999-06-30 | 2001-01-31 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| KR20030060904A (ko) | 2000-10-06 | 2003-07-16 | 뉴로젠 코포레이션 | Ｃｒｆ 수용체 조절자로서 벤즈이미다졸 및 인돌 유도체 |
| US6951848B2 (en) | 2001-03-12 | 2005-10-04 | Millennium Pharmaceuticals, Inc., | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor |
| ATE375350T1 (de) | 2002-02-21 | 2007-10-15 | Lilly Co Eli | Modulatoren von peroxisome proliferator- aktivierten rezeptoren |
| US7189716B2 (en) | 2003-01-03 | 2007-03-13 | Bristol-Myers Squibb Company | Tyrosine kinase inhibitors |
| US7312215B2 (en) | 2003-07-29 | 2007-12-25 | Bristol-Myers Squibb Company | Benzimidazole C-2 heterocycles as kinase inhibitors |
| JP2008501714A (ja) | 2004-06-04 | 2008-01-24 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼインヒビター |
| WO2006124780A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase |
| WO2006136823A1 (en) | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Heterocyclic containing amines as kinase b inhibitors |
| EP1878724A1 (en) | 2006-07-15 | 2008-01-16 | sanofi-aventis | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles |
| AU2007329480A1 (en) | 2006-12-05 | 2008-06-12 | National Chio Tung University | Indazole compounds |
| WO2009000413A1 (en) | 2007-06-26 | 2008-12-31 | Sanofi-Aventis | A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles |
| WO2009023179A2 (en) | 2007-08-10 | 2009-02-19 | Genelabs Technologies, Inc. | Nitrogen containing bicyclic chemical entities for treating viral infections |
| CA2709883A1 (en) | 2007-12-19 | 2009-06-25 | The Scripps Research Institute | Benzimidazoles and analogs as rho kinase inhibitors |
| US8501957B2 (en) | 2008-12-10 | 2013-08-06 | China Medical University | Benzimidazole compounds and their use as anticancer agents |
| WO2010068287A2 (en) | 2008-12-11 | 2010-06-17 | Angion Biomedica Corp. | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| US20120040916A1 (en) | 2008-12-22 | 2012-02-16 | Massachusetts Institute Of Technology | Molecular inhibitors of the wnt/beta-catenin pathway |
| EP2501696B1 (en) | 2009-10-15 | 2016-12-28 | Guerbet | Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases |
| US8455516B2 (en) | 2010-01-15 | 2013-06-04 | Touro University | HIV-1 fusion inhibitors and methods |
| WO2011097607A1 (en) | 2010-02-08 | 2011-08-11 | Southern Research Institute | Anti-viral treatment and assay to screen for anti-viral agent |
| US8946230B2 (en) | 2010-05-13 | 2015-02-03 | Amgen Inc. | Aryl- and heteroaryl- nitrogen-heterocyclic compounds as PDE10 inhibitors |
| EP2397471A1 (en) | 2010-06-16 | 2011-12-21 | China Medical University | Benzimidazole compounds and their use |
| JP5850503B2 (ja) | 2010-09-14 | 2016-02-03 | 北海道公立大学法人 札幌医科大学 | 筋ジストロフィーを処置するための組成物 |
| CA2825028A1 (en) | 2011-02-09 | 2012-08-16 | F. Hoffman-La Roche Ag | Heterocyclic compounds as pi3 kinase inhibitors |
| EP2681200A4 (en) | 2011-03-03 | 2015-05-27 | Zalicus Pharmaceuticals Ltd | INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL |
| JP2014114212A (ja) | 2011-03-29 | 2014-06-26 | Dainippon Sumitomo Pharma Co Ltd | 新規ベンズイミダゾール誘導体 |
| TW201348231A (zh) | 2012-02-29 | 2013-12-01 | Amgen Inc | 雜雙環化合物 |
| US9550737B2 (en) | 2012-06-11 | 2017-01-24 | Ucb Biopharma Sprl | TNF -α modulating benzimidazoles |
| US9212209B2 (en) | 2012-07-13 | 2015-12-15 | Indiana University Research And Technology Corporation | Screening methods for spinal muscular atrophy |
| JP2016000697A (ja) | 2012-10-02 | 2016-01-07 | 大日本住友製薬株式会社 | ピリミジン誘導体 |
| JP2014073982A (ja) | 2012-10-03 | 2014-04-24 | Dainippon Sumitomo Pharma Co Ltd | 新規ベンズイミダゾール誘導体からなる医薬 |
| US9757379B2 (en) | 2012-11-14 | 2017-09-12 | The Board Of Regents Of The University Of Texas System | Inhibition of HIF-2α heterodimerization with HIF1β (ARNT) |
| WO2014157382A1 (ja) | 2013-03-29 | 2014-10-02 | 味の素株式会社 | スフィンゴシンキナーゼ阻害剤 |
| PL231063B1 (pl) | 2013-04-10 | 2019-01-31 | Oncoarendi Therapeutics Spolka Z Ograniczona Odpowiedzialnoscia | Pochodne 1-(podstawionej sulfonylo)-2-aminoimidazoliny jako środki przeciwnowotworowe |
| WO2015023958A1 (en) | 2013-08-15 | 2015-02-19 | The University Of Kansas | Toll-like receptor agonists |
| GB201321741D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| JP6785217B2 (ja) | 2014-07-31 | 2020-11-18 | インスティチュート パスツール コリア | ２−アミノ−ベンゾイミダゾール誘導体ならびにこれらの５−リポキシゲナーゼおよび／またはプロスタグランジンｅシンターゼ阻害剤としての使用 |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506658D0 (en) * | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| EP3307798B2 (en) | 2015-06-12 | 2024-06-05 | Transitions Optical, Inc. | Alignment compounds |
| CN108137539B (zh) | 2015-08-12 | 2022-01-11 | 尼奥迈德研究所 | 取代的苯并咪唑、它们的制备和它们作为药物的用途 |
| TW201726130A (zh) | 2015-10-02 | 2017-08-01 | 基利科學股份有限公司 | 用於治療癌症之組合療法 |
| US20180354909A1 (en) | 2015-12-11 | 2018-12-13 | The Board Of Regents Of The University Of Texas System | Substituted benzimidazolium, pyrido-imidazolium, or pyrazino-imidazolium compounds as chemotherapeutics |
| WO2017106568A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer |
| WO2017223243A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| GB201617627D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201617630D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2018097976A1 (en) | 2016-11-22 | 2018-05-31 | Gilead Sciences, Inc. | Synthesis of a compound that modulates the activity of bromodomain-containing proteins |
-
2016
- 2016-10-18 GB GBGB1617630.7A patent/GB201617630D0/en not_active Ceased
-
2017
- 2017-10-18 WO PCT/GB2017/053152 patent/WO2018073586A1/en not_active Ceased
- 2017-10-18 DK DK17790813.4T patent/DK3529248T3/da active
- 2017-10-18 LT LTEP17790813.4T patent/LT3529248T/lt unknown
- 2017-10-18 RS RS20201314A patent/RS61007B1/sr unknown
- 2017-10-18 AU AU2017346453A patent/AU2017346453B2/en active Active
- 2017-10-18 CN CN201780072401.XA patent/CN110049983B/zh active Active
- 2017-10-18 HR HRP20201444TT patent/HRP20201444T1/hr unknown
- 2017-10-18 US US16/341,631 patent/US10696666B2/en active Active
- 2017-10-18 EA EA201990643A patent/EA201990643A1/ru unknown
- 2017-10-18 ES ES17790813T patent/ES2828504T3/es active Active
- 2017-10-18 EP EP17790813.4A patent/EP3529248B1/en active Active
- 2017-10-18 SG SG11201903155XA patent/SG11201903155XA/en unknown
- 2017-10-18 SM SM20200593T patent/SMT202000593T1/it unknown
- 2017-10-18 PT PT177908134T patent/PT3529248T/pt unknown
- 2017-10-18 JP JP2019520588A patent/JP7152393B2/ja active Active
- 2017-10-18 HU HUE17790813A patent/HUE052443T2/hu unknown
- 2017-10-18 MX MX2019004113A patent/MX384438B/es unknown
- 2017-10-18 KR KR1020197014352A patent/KR102578786B1/ko active Active
- 2017-10-18 SI SI201730402T patent/SI3529248T1/sl unknown
-
2019
- 2019-04-12 ZA ZA2019/02334A patent/ZA201902334B/en unknown
- 2019-04-14 IL IL266017A patent/IL266017B/en unknown
-
2020
- 2020-05-14 US US15/931,782 patent/US11377443B2/en active Active
- 2020-11-19 CY CY20201101096T patent/CY1123666T1/el unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007056593A2 (en) * | 2005-11-08 | 2007-05-18 | Choongwae Pharma Corporation | α-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS |
| WO2011085039A2 (en) * | 2010-01-05 | 2011-07-14 | The Johns Hopkins University | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies |
| CN105324379A (zh) * | 2013-05-09 | 2016-02-10 | 吉里德科学公司 | 作为溴结构域抑制剂的苯并咪唑衍生物 |
| CN105492439A (zh) * | 2013-06-21 | 2016-04-13 | 齐尼思表观遗传学公司 | 作为溴结构域抑制剂的新取代的双环化合物 |
| WO2016086200A1 (en) * | 2014-11-27 | 2016-06-02 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110049983B (zh) | 药物化合物 | |
| JP7051829B2 (ja) | Ｄｎｍｔ１の阻害剤としての置換ピリジン | |
| CN113645971B (zh) | 化合物及其用途 | |
| JP6871864B2 (ja) | イソオキサゾリル置換ベンズイミダゾール類 | |
| TWI713847B (zh) | 治療活性組合物及其使用方法 | |
| CN113474346A (zh) | 用于抑制泛素特异性蛋白酶1的组合物 | |
| CN110036002B (zh) | 药物化合物 | |
| JP2020040989A (ja) | ブルトン型チロシンキナーゼ（ｂｔｋ）インヒビターとしての多フルオロ置換化合物 | |
| TW202400576A (zh) | 嘧啶類化合物、其製備方法及其醫藥用途 | |
| TW201706257A (zh) | 化合物 | |
| WO2022194269A1 (zh) | 新型egfr降解剂 | |
| JP6795588B2 (ja) | ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド | |
| EP3286188A1 (en) | Isoxazolyl substituted imidazopyridines | |
| CN112384509A (zh) | 弗林蛋白酶抑制剂 | |
| CN114786778A (zh) | 治疗性化合物 | |
| CN113348170A (zh) | 联苯类衍生物抑制剂、其制备方法和应用 | |
| CN115348961A (zh) | 杂环pad4抑制剂 | |
| KR20160135183A (ko) | 복소환 술폰아미드 유도체 및 그것을 함유하는 의약 | |
| TW201734020A (zh) | 布魯頓氏酪胺酸激酶抑制劑及其使用方法 | |
| TW201910312A (zh) | 環狀胺衍生物及其醫藥用途 | |
| CN111315750B (zh) | 作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物 | |
| CA3039641C (en) | Arylimidazolyl isoxazole compounds and their use as modulators of p300 and/or cbp | |
| HK40117941A (zh) | 包含抗癌剂和对前列腺素e2受体具有抑制活性的新化合物的用於治疗癌症的药物组合物 | |
| WO2023137634A1 (zh) | 三并环化合物、其制备、药物组合物及应用 | |
| JP2025536323A (ja) | 縮合二環式化合物ならびにＭｅｒ阻害剤およびＡｘｌ阻害剤としてのその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |